Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PoCCardio

Financiado

Cerrado

Personalised Medicine by using an Advanced Point of Care Tool for Stratified Tre...

Personalised Medicine by using an Advanced Point of Care Tool for Stratified Treatment in High Risk Cardiovascular Patients PoCCardio Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Besides established risk factors such as elevated blood pressure, blood glucose or lipid levels, circulating proteomic as well as genetic markers allow furth... ver más

30/11/2028

Líder desconocido

13M€

Presupuesto del proyecto: 13M€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-08

HORIZON-HLTH-2022-TOOL-11-02: New methods for the effective use o... Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one o...

I+D

Próximamente

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2023-11-08
Fecha Fin: 2028-11-30

Líder del proyecto Líder desconocido

Presupuesto del proyecto 13M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Besides established risk factors such as elevated blood pressure, blood glucose or lipid levels, circulating proteomic as well as genetic markers allow further stratification of patients. While some of these markers can be measured routinely in low-threshold healthcare institutions, others require access to highly specialized and costly laboratory environment which usually can be found only within larger tertiary settings. The aim of this project is to advance and tailor a point-of-care (PoC) tool, which was recently developed within the framework of HORIZON 2020. Using cutting-edge lab-on-a-chip (LoC) and microfluidic technology, the tool will be further developed to measure qualified biomarkers and polymorphisms from finger prick blood, in order to help identify, classify and monitor cardiovascular patients at high risk. The clinical validation of these biomarkers and the PoC tool will then be performed in a prospective, randomised multinational trial which will include only existing and approved pharmaceuticals. Based on their specific pattern of qualified biomarkers, patients will be assigned either to standard pharmacological treatment, or tailored intensified treatment. Data derived from the clinical validation study will constitute a rich source for complex AI-powered computational analysis to explore potential predictors for primary and secondary outcome parameters. The trial will further provide the scientific foundation to support regulatory authorities in regard to approval of companion diagnostics, and recommendations for the prescription of drugs, respectively. Overall, this project aims to improve care and treatment efficacy in CVD patients through an advanced biomarker-driven PoC-based personalised medicine. To achieve these aims, a well-balanced consortium of five academic research partners and two SMEs has been brought together.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores